Igor A. Sherman
Directeur Général chez Alpha Cancer Technologies, Inc.
Profil
Igor A.
Sherman is the founder of Alpha Cancer Technologies, Inc. founded in 2008, where he holds the title of President & Chief Executive Officer.
He also worked as a Director-Scientific Affairs at YM BioSciences, Inc. and as an Analyst at JPMorgan Securities LLC from 2005 to 2010.
Dr. Sherman received his undergraduate degree from the University of Connecticut in 2003.
Postes actifs de Igor A. Sherman
| Sociétés | Poste | Début |
|---|---|---|
Alpha Cancer Technologies, Inc.
 Alpha Cancer Technologies, Inc. Pharmaceuticals: MajorHealth Technology Alpha Cancer Technologies, Inc. develops oncology and auto-immune disease treatments. Its products include Alpha Fetoprotein, immunotherapy and targeted chemotherapy platform. The company was founded by Igor A. Sherman in 2008 and is headquartered in Toronto, Canada. | Directeur Général | 01/01/2008 |
Anciens postes connus de Igor A. Sherman
| Sociétés | Poste | Fin |
|---|---|---|
JPMorgan Securities LLC
 JPMorgan Securities LLC Investment Banks/BrokersFinance JPMorgan Securities LLC (JPMS) is a securities brokerage firm headquartered in New York City. The firm was founded in 1985 and is a subsidiary of JPMorgan Broker-Dealer Holdings, Inc., ultimately held by JPMorgan Chase & Co., Inc. (NYSE: JPM). JPMS provides research on fixed income, credit, derivatives, emerging markets, foreign exchange, structured finance, technical analysis and bond indices. Their equity analysts cover equities throughout North America, EMEA, Asia/Pacific and the emerging markets. The firm's fixed income team formulates trading and portfolio recommendations for investors in global bonds and other fixed-income markets based on valuations, analytics and market dynamics. | Analyst-Fixed Income | 01/08/2010 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Directeur Technique/Scientifique/R&D | - |
Formation de Igor A. Sherman
| University of Connecticut | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
JPMorgan Securities LLC
JPMorgan Securities LLC Investment Banks/BrokersFinance JPMorgan Securities LLC (JPMS) is a securities brokerage firm headquartered in New York City. The firm was founded in 1985 and is a subsidiary of JPMorgan Broker-Dealer Holdings, Inc., ultimately held by JPMorgan Chase & Co., Inc. (NYSE: JPM). JPMS provides research on fixed income, credit, derivatives, emerging markets, foreign exchange, structured finance, technical analysis and bond indices. Their equity analysts cover equities throughout North America, EMEA, Asia/Pacific and the emerging markets. The firm's fixed income team formulates trading and portfolio recommendations for investors in global bonds and other fixed-income markets based on valuations, analytics and market dynamics. | Finance |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Alpha Cancer Technologies, Inc.
Alpha Cancer Technologies, Inc. Pharmaceuticals: MajorHealth Technology Alpha Cancer Technologies, Inc. develops oncology and auto-immune disease treatments. Its products include Alpha Fetoprotein, immunotherapy and targeted chemotherapy platform. The company was founded by Igor A. Sherman in 2008 and is headquartered in Toronto, Canada. | Health Technology |